Table 1 Retrospective cohort: patient characteristics
Characteristics | n. (%) |
|---|---|
Total n. of patients | 174 (100) |
Sex | |
Male | 80 (46) |
Female | 94 (54) |
Median age (range) | 62 years (28–79) |
ECOG Performance Status | |
0 | 106 (61) |
1 | 52 (30) |
2 | 16 (9) |
Site of primary tumor | |
Intrahepatic | 86 (49) |
Extrahepatic | 37 (21) |
Gallbladder | 34 (20) |
Ampullary | 17 (10) |
CA19.9 before second-line CT | |
< Median value (157 U/ml) | 71 (41) |
≥ Median value (157 U/ml) | 83 (48) |
Data missing | 20 (11) |
Previous response to first-line CT | |
Partial response | 37 (21.3) |
Stable disease | 70 (40.3) |
Progressive disease | 67 (38.4) |
Median PFS to first-line CT | 5.8 months |
Third-line CT received | 74 (43) |
Platinum plus or minus gemcitabine or fluoropyrimidine | 24 (14) |
Irinotecan plus or minus 5-fluorouracil or capecitabine | 17 (10) |
Monotherapy with 5-fluorouracil or capecitabine | 10 (6) |
Monotherapy with paclitaxel or docetaxel | 7 (4) |
Monotherapy with epirubicin | 5 (3) |
Other regimens | 11 (6) |